Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study
Matthew S. Davids(Dana-Farber Cancer Institute), Yifan Zhai(ASKA Pharmaceutical (Japan)), Boyd Mudenda, Tanya Siddiqi(City Of Hope National Medical Center), Ivan Muzhychuk, Allison Winter(Cleveland Clinic), Asher Chanan‐Khan(WinnMed), Olena Kyselova(Kyiv International Institute of Sociology (Ukraine)), Hengbang Wang, Robert Winkler, Vinod Ganju(Peninsula Health), Б. А. Бакиров(Bashkir State Medical University), Zi Chen(Central South University), Mohammad Ahmad, Ganna Usenko(Regional Clinical Hospital named after II Mechnikov), Mingyu Li(Huazhong University of Science and Technology), Asit K. De, Divya J. Mekala(Vifor Pharma (United States)), Iurii Osipov, Sikander Ailawadhi(Jacksonville College), Alexander G. Myasnikov(Petrozavodsk State University), Laura Glass(Vifor Pharma (United States)), Zhiyan Liang(East China University of Science and Technology), Vladimir Ivanov(Federal Almazov North-West Medical Research Centre), Paula Marlton(The University of Queensland), Elena Borisenkova(Murmansk Regional Clinical Hospital), Andrei Proydakov(Institute of Chemistry, Komi Science Center), Larysa Nogaieva(Cherkasy State Technological University), Dajun Yang(Ascendis Pharma (Denmark)), Tamila Lysa, Tetiana Perekhrestenko, Olga Samoilova, Vallari Shah(Bridge Pharma (United States)), Olena Karpenko(Kyiv City Clinical Oncology Center), Tatyana Konstantinova(Regional Children's Clinical Hospital No. 1), Nashat Gabrail(Gabrail Cancer Center), Olga Uspenskaya, Les M. Lukavetskyy(Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine), Iryna Kryachock(National Cancer Institute), Tommy Fu
Cited by 6
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Genomic responses in mouse models poorly mimic human inflammatory diseases
|Proceedings of the National Academy of Sciences|2013|3k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k